Discovery of serum metabolites for diagnosis of progression of mild cognitive impairment to Alzheimer's disease using an optimized metabolomics method
0303 health sciences
03 medical and health sciences
3. Good health
DOI:
10.1039/c5ra19349d
Publication Date:
2016-01-05T09:30:21Z
AUTHORS (6)
ABSTRACT
A nontargeted metabolomics approach was developed to examine metabolic differences in serum samples from the mild cognitive impairment and Alzheimer's disease subjects.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (22)
CITATIONS (60)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....